C-Type Natriuretic Peptide(CNP)(1-22),human TFA

位置：首页 > 产品库 > C-Type Natriuretic Peptide(CNP)(1-22),human TFA

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

规格:	98%
分子量:	2311.62

包装与价格：

包装	价格(元)
500ug	询价
1mg	询价
5mg	询价

C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP).
货号:ajcx35698
CAS:1966153-17-2
分子式:C95H158F3N27O30S3
分子量：2311.62
溶解度:H2O : 2 mg/mL (0.87 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP). C-Type Natriuretic Peptide (CNP) is a selective agonist of natriuretic peptide receptors NPR-B and C (Kds = 7, and 10.8 pM)^[1].

C-Type Natriuretic Peptide (CNP) (1-22), significantly promoted longitudinal bone growth in an organ culture experiment using tibiae from fetal mice^[2]. C-Type Natriuretic Peptide (CNP) (1-22) in vivo administration might attenuate cardiac remodeling after myocardial infarction (MI) through its antifibrotic and antihypertrophic action^[3]. NPR-B-mediated cGMP production after CNP administration specifically acted on the pylorus, colon, and rectum and contributed to gastric emptying^[1].

参考文献:
[1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9.
[2]. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11 695-11 700
[3]. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. 2005.J Am Coll Cardiol 45:608-616

Protocol:

Animal experiment [2]:
Animal models	Four-week-old female ddY mice
Preparation Method	Mice were separated into four groups: the untreated (baseline) group, the 2 mg/kg C-Type Natriuretic Peptide (CNP) group, the 1 mg/kg C-Type Natriuretic Peptide (CNP) group, and the vehicle (normal saline) group. C-Type Natriuretic Peptide (CNP) and vehicle were administered intravenously.
Dosage form	Intravenously injection, 1 or 2 mg/kg
Applications	In the pylorus and rectum, after 2 mg/kg C-Type Natriuretic Peptide (CNP) was administered, cGMP production was remarkably increased as early as 1 minute compared with that after 1 mg/kg C-Type Natriuretic Peptide (CNP) was administered
参考文献: [1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9.